Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
523 people get NUVA articles and Market Currents by email alert.
Get email alerts on NUVA »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
NuVasive: Earnings Miss, A Risk Or An Opportunity?Kapitall • Thu, Oct 4, 2012 -
-
-
-
-
-
NuVasive: Momentum Breeds MomentumTraderMark • Tue, Jun 23, 2009 -
NuVasive: Not for the Faint of HeartTraderMark • Mon, Apr 27, 2009
-
Even in a Depression, We'll Need NuVasiveTraderMark • Thu, Nov 20, 2008
-
Investors Business Daily on NuVasiveTraderMark • Tue, Nov 4, 2008
-
Expect Big Things from NuvasiveDouglas Cress • Mon, Mar 10, 2008
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Earnings Preview: Stryker CorporationVytautas Drumelis • Tue, Jul 17, 2012 -
-
-
Earnings Preview: AngioDynamicsVytautas Drumelis • Thu, Jul 5, 2012
-
-
-
4 Outperforming Healthcare Stocks With Strong Sales TrendsKapitall • Sun, May 13, 2012
-
-
Review Of Analyst Upgrades This Week - Part IVThe Value Investor • Mon, May 7, 2012
-
Biotechnology And Drugs Stocks To Watch For Next WeekStockPandit • Wed, Apr 25, 2012
-
NuVasive's CEO Discusses Q3 2012 Results - Earnings Call TranscriptWed, Oct 24, 2012 • 1 Comment
-
NuVasive Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
NuVasive Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
NuVasive, Inc., Q1 2009 Earnings Call TranscriptThu, Apr 23, 2009
-
NuVasive Inc. Q4 2008 Earnings Call TranscriptWed, Feb 25, 2009
-
NuVasive Q3 2008 Earnings Call TranscriptWed, Oct 22, 2008
-
NuVasive, Inc., Q2 2008 Earnings Call TranscriptThu, Jul 24, 2008
-
NuVasive, Inc. Q1 2008 Earnings Call TranscriptWed, Apr 23, 2008
-
NuVasive Q4 2007 Earnings Call TranscriptFri, Feb 22, 2008
-
Marketwire (May 31, 2013)
-
Marketwire (May 6, 2013)
-
Marketwire (May 1, 2013)
-
Marketwire (Apr 30, 2013)
-
Marketwire (Apr 24, 2013)
-
Marketwire (Apr 16, 2013)
-
Marketwire (Apr 11, 2013)
-
Marketwire (Mar 27, 2013)
-
Marketwire (Mar 19, 2013)
-
Marketwire (Feb 26, 2013)
-
Marketwire (Feb 26, 2013)
-
Marketwire (Feb 19, 2013)
-
Marketwire (Feb 7, 2013)
-
Marketwire (Feb 5, 2013)
-
Marketwire (Jan 9, 2013)
-
Marketwire (Jan 2, 2013)
-
Marketwire (Dec 17, 2012)
-
Marketwire (Dec 13, 2012)
-
Marketwire (Dec 10, 2012)
NUVA vs. ETF Alternatives
Company Description
Currently, there's no company description for NUVA.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Thursday, October 4, 2012, 9:10 AM
Premarket gainers: VRNG +7%. STEM +6%.
Losers: NUVA -32%. INFA -23%. Comment! [On the Move] - Wednesday, October 3, 2012, 4:30 PM NuVasive (NUVA) lowers its Q3 outlook, saying it anticipates revenue to be around $147M, below earlier expectations for flat sequential revenue growth. The company experienced unusually high account churn related primarily to the growth of surgeon participation in physician-owned distributorships and to increasingly aggressive tactics from its competitors. Additionally, it heard from many surgeon customers of "increased delays and denials from insurance payers", and will provide revised full year guidance on its October 29th earnings conference call. Shares -21% AH. Comment! [Healthcare]
- Friday, September 21, 2012, 2:16 PM NuVasive (NUVA +3.8%) trades up after Brean Murray initiates the shares with a Buy and a $30 price target. The firm says that with as solid a pipeline as NUVA has, expectations for the medical-device company look conservative now that it has "successfully defended" its core U.S. spinal-products business. Comment! [Healthcare, On the Move]
- Tuesday, September 11, 2012, 11:50 AM Shares of Nuvasive (NUVA +2.3%) gain after an appeals court reverses an order by a lower court which forced the company to pay $60M to a competitor for trademark infringement. The lawsuit, filed by Neurovision Medical Products in September 2009, sought to cancel NuVasive's trademark on its nerve monitoring platform that carried it's name. Comment! [Healthcare, On the Move]
- Wednesday, July 25, 2012, 5:43 PM NuVasive (NUVA): Q2 EPS of $0.27 beats by $0.04. Revenue of $154.4M (+16.1% Y/Y) in line. Shares +1% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Thursday, July 19, 2012, 12:04 PM ThinkEquity says that its channel checks show the spine market remains stable despite the challenging environment, and that Nuvasive (NUVA -0.7%) is poised to beat Q2 Street estimates. The firm ups its price target to $30 from $25 and reiterates a Buy. Comment! [Healthcare, Earnings]
- Thursday, June 21, 2012, 12:26 PM Shares of NuVasive (NUVA -0.9%) aren't getting much help today from upgrade to Outperform at Wells Fargo as the stock struggles to break through key technical resistance levels. Wells cites improvements in the spine market and the company's conservative 2012 guidance for the upgrade. The firm alos raised its price target range to $29 - $31 from $17 - $18. Comment! [Healthcare]
- Monday, June 18, 2012, 3:57 PM NuVasive (NUVA +5.7%) gets a bump from some positive comments out of JMP Securities today, saying that after surveying top hospital executives, it believes that growth in spine surgery and back pain surgery is exceeding expectations. The firm notes that NUVA has little exposure to Europe, and ups its price target to $25 from $21. Comment! [Healthcare, On the Move]
- Wednesday, June 6, 2012, 11:06 AM NuVasive (NUVA +5.6%) gets a pop from an upgrade to Outperform at RBC Capital. The firm says that the results of a recent survey of U.S. spine surgeons show the Street may be underestimating the near-term sustainability of the medical device company's U.S. lumbar revenue growth rate. Comment! [Healthcare, On the Move]
- Tuesday, May 1, 2012, 11:47 AM Spinal implant maker NuVasive (NUVA +17%) pops after its Q1 results easily beat estimates, coming in at the high end of the expected range. Revenue jumped 21% Y/Y on strong sales of its minimally invasive spinal surgery products. William Blair and Baird both upgrade the stock on the back of the better than expected results. Comment! [Healthcare, Earnings, On the Move]
-
Tuesday, May 1, 2012, 9:10 AM
Premarket gainers: PLXT +65%. PFCB +30%. NUVA +18%. CAR +14%. CETV +15%. VECO +13%. HUN +10%. YGE +8%. LYG +7%. SHLD +7%. CAKE +6%. TSL +6%. HTZ +6%. WFR +4%. ANF +4%. STP +4%. AKAM +4%. ARNA +4%. FSLR +3%. JASO +3%. CLWR +3%. PWER +3%.
Losers: COP -22%. PBY -21%. IDTI -12%. VPHM -11%. NG -7%. DPZ -7%. WMS -6%. EMR -5%. XRAY -4%. NMR -4%. NZGA -3%. URI -3%. AVP -3%. ACI -3%. Comment! [On the Move] - Monday, April 30, 2012, 5:17 PM NuVasive (NUVA): Q1 EPS of $0.20 beats by $0.02. Revenue of $151.7M (+21.8% Y/Y) beats by $8M. Shares +4.2% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Thursday, March 15, 2012, 3:51 PM NuVasive (NUVA +7.2%) shares are upgraded to Outperform by JMP Securities on signs that the fundamentals of the slumping market for spine products have turned a corner. The firm says NUVA is well positioned to benefit from what should prove a long-term trend because of its focus on minimally invasive surgery and its acquisition of Impulse Monitoring. Comment! [Healthcare, On the Move]
- Wednesday, February 22, 2012, 6:11 PM NuVasive (NUVA): Q4 EPS of $0.27 beats by $0.05. Revenue of $150M (+16% Y/Y) beats by $2M. (PR) Comment! [Earnings, Healthcare]
- Thursday, January 26, 2012, 11:39 AM NuVasive (NUVA -5.5%) drops back down after racking up a double-digit gain yesterday when a federal court denied Medtronic's (MDT -0.3%) request for a permanent inunction. It's not the end of the road for the company with more courtroom battles upcoming to see if it will have to pay a $101M jury award for patent infringement. Comment! [Healthcare, On the Move]
- Thursday, January 12, 2012, 12:53 PM NuVasive (NUVA -3.2%) gives back a little today, despite being upgraded to Above Average at Caris. The stock has ramped nearly 15% higher over the past two days, following an earlier upgrade by ThinkEquity and an upbeat preliminary FY11 earnings report. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Andrew Shapiro
"Sparton Corp Sell-Off Presents Attractive Valuation And Rebound Opportunity" http://seekingalpha.com/a/67zo SPA GR, NOC, NUVA, PH, RTN, SI - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES